Recombinant human VEGF-C increases dural lymphangiogenesis and eliminates both soluble and insoluble Aβ in Alzheimer’s disease (AD) models, which also provides fresh suggestions for AD treatments [182]. Here, VEGFC is linked to Alzheimer disease.